The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by University of Vermont.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
American Cancer Society, Inc.
Information provided by:
University of Vermont
ClinicalTrials.gov Identifier:
NCT01341171
First received: July 7, 2010
Last updated: April 21, 2011
Last verified: April 2011

July 7, 2010
April 21, 2011
August 2009
October 2010   (final data collection date for primary outcome measure)
Angiogenic Protein levels [ Time Frame: following 6 months of therapy ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01341171 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins
Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins

Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.

Not Provided
Observational
Not Provided
Not Provided
Retention:   Samples Without DNA
Description:

serum, plasma, platelet activated samples

Non-Probability Sample

Women using tamoxifen or aromatase inhibitor therapy for greater than 6 months

Breast Cancer
Not Provided
tamoxifen or aromatase inhibitors
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
September 2012
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist

Exclusion Criteria:

  • Use of heparin, warfarin
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01341171
V0805
No
Chris E. Holmes, MD, PhD, University of Vermont
University of Vermont
American Cancer Society, Inc.
Principal Investigator: Chris E Holmes, MD, PhD University of Vermont
University of Vermont
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP